A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency’s ‘Suspected Adverse Drug Reactions’ Database
Open accessThe DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Abstract
Introduction The gabapentinoids pregabalin and gabapentin are being increasingly prescribed for a range of clinical conditions. Recently, although gabapentinoids at therapeutic dosages may present with low addictive liability levels, cases of misuse and rising numbers of related fatalities have been reported.Objectives The aim of the study was to identify and assess cases of gabapentinoid misuse or dependence as reported to the European Medicines Agency's EudraVigilance database, to identify the magnitude of this problem and the characteristics of these reactions.Methods All spontaneous reports of both gabapentin- (2004-2015) and pregabalin- (2006-2015) related misuse/abuse/dependence were retrieved. A descriptive analysis by source, sex, age, and type of report was performed.Results From the EudraVigilance database 7639 (6.6 % of a total of 115,616) and 4301 (4.8 % of 90,166) adverse drug reaction reports of misuse/abuse/dependence were, respectively, associated with pregabalin and gabapentin, with an overall reporting frequency increasing over time. For both molecules, subjects typically involved were female adults. A total of 27 and 86 fatalities, respectively, associated with pregabalin and gabapentin, and mostly in combination with opioids, were identified. Analysis of proportional reporting ratios for drug abuse/dependence/intentional product misuse values seem to indicate that these adverse drug reactions were more frequently reported for pregabalin (1.25, 1.39, and 1.58, respectively) compared with gabapentin.Conclusions Despite data collection/methodological approach limitations, the present data seem to suggest that gabapentinoid misuse may be a cause for concern, especially in patients with a history of substance misuse. Hence, healthcare professionals should be vigilant when prescribing these molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“All these actions are likely contributing to both its significant psychoactive effects and addictive liability issues (43-44; Table 1).”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [43]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin
Bockbrader, H. N., Wesche, D., Miller, R., Chapel, S., Janiczek, N., & Burger, P. (2010) · Clinical Pharmacokinetics · doi:10.2165/11536200-000000000-00000 · Cited by 690
Pharmaceutical Overdose Deaths, United States, 2010
Jones, C. M., Mack, K. A., & Paulozzi, L. J. (2013) · JAMA · doi:10.1001/jama.2013.272 · Cited by 678
Novel psychoactive substances of interest for psychiatry
Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015) · World Psychiatry · doi:10.1002/wps.20174 · Cited by 321
Self-citationNagakura, Y., Oe, T., Aoki, T., & Matsuoka, N. (2009) · Pain · doi:10.1016/j.pain.2009.05.024 · Cited by 256
Misuse and Abuse of Pregabalin and Gabapentin: Cause for Concern?
Schifano, F. (2014) · CNS Drugs · doi:10.1007/s40263-014-0164-4 · Cited by 250
Self-citationSchifano, F., D’Offizi, S., Piccione, M., Corazza, O., Deluca, P., Davey, Z., Di Melchiorre, G., Di Furia, L., Farré, M., Flesland, L., et al. (2011) · Psychotherapy and Psychosomatics · doi:10.1159/000321079 · Cited by 187
Self-citationSchwan, S., Sundström, A., Stjernberg, E., Hallberg, E., & Hallberg, P. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0853-y · Cited by 169
Baird, C. R. W., Fox, P., & Colvin, L. A. (2014) · European Addiction Research · doi:10.1159/000355268 · Cited by 146
Pregabalin abuse and dependence in Germany: results from a database query
Gahr, M., Freudenmann, R. W., Hiemke, C., Kölle, M. A., & Schönfeldt‐Lecuona, C. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1464-6 · Cited by 143
Profiles of pregabalin and gabapentin abuse by postmortem toxicology
Häkkinen, M., Vuori, E., Kalso, E. A., Gergov, M., & Ojanperä, I. A. (2014) · Forensic Science International · doi:10.1016/j.forsciint.2014.04.028 · Cited by 139
Pregabalin abuse among opiate addicted patients
Grosshans, M., Leménager, T., Vollmert, C., Kaemmerer, N., Schreiner, R., Mutschler, J., Wagner, X., Kiefer, F., & Hermann, D. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1578-5 · Cited by 136
Pregabalin: A Review of its Use in Adults with Generalized Anxiety Disorder
Frampton, J. E. (2014) · CNS Drugs · doi:10.1007/s40263-014-0192-0 · Cited by 128
Pregabalin Abuse, Dependence, and Withdrawal: A Case Report
Grosshans, M., Mutschler, J., Hermann, D., Klein, O., Dreßing, H. R., Kiefer, F., & Mann, K. F. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09091269 · Cited by 108
Kalso, E., Aldington, D. J., & Moore, R. A. (2013) · BMJ · doi:10.1136/bmj.f7339 · Cited by 107
Misuse of the γ‐aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK
Kapil, V., Green, J. L., Le Lait, M., Wood, D. M., & Dargan, P. I. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12277 · Cited by 98
Gabapentin Toxicity in Patients with Chronic Kidney Disease: A Preventable Cause of Morbidity
Zand, L., McKian, K. P., & Qian, Q. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.09.030 · Cited by 92
Sex-related differences in migraine
Finocchi, C., & Strada, L. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1772-y · Cited by 85
Substance misuse of gabapentin
Smith, B. H., Higgins, C., Baldacchino, A., Kidd, B., & Bannister, J. (2012) · British Journal of General Practice · doi:10.3399/bjgp12x653516 · Cited by 85
Prescription medication misuse among opioid dependent patients seeking inpatient detoxification
Wilens, T., Zulauf, C., Ryland, D., Carrellas, N., & Catalina‐Wellington, I. (2015) · The American Journal on Addictions · doi:10.1111/ajad.12159 · Cited by 79
Fatal toxicity index of medicinal drugs based on a comprehensive toxicology database
Ojanperä, I., Kriikku, P., & Vuori, E. (2016) · International Journal of Legal Medicine · doi:10.1007/s00414-016-1358-8 · Cited by 76 · cited 1×
“Although this finding is in itself interesting, to be able to calculate properly the gabapentinoid ‘fatal toxicity index’ [69] one would need to have the total number of patients exposed to either pregabalin or gabapentin.”
BackgroundThe Potential of Pregabalin in Neurology, Psychiatry and Addiction: A Qualitative Overview
Martinotti, G., Lupi, M., Sarchione, F., Santacroce, R., Salone, A., Berardis, D., Serroni, N., Cavuto, M., Signorelli, M., Aguglia, E., et al. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990425 · Cited by 72
O'Donnell, S., Vanderloo, S., McRae, L., Onysko, J., Patten, S. B., & Pelletier, L. (2016) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796015000463 · Cited by 66
Clinical Outcomes in Newer Anticonvulsant Overdose: A Poison Center Observational Study
Wills, B. K., Reynolds, P. S., Chu, E. C., Murphy, C. M., Cumpston, K. L., Stromberg, P. E., & Rose, R. (2014) · Journal of Medical Toxicology · doi:10.1007/s13181-014-0384-5 · Cited by 64
Factors associated with pregabalin dispensing at higher than the approved maximum dose
Bodén, R., Wettermark, B., Brandt, L., & Kieler, H. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1594-5 · Cited by 64
Concerns About Pregabalin: Further Experience With Its Potential of Causing Addictive Behaviors
Gahr, M., Franke, B., Freudenmann, R. W., Kölle, M. A., & Schönfeldt‐Lecuona, C. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3182872718 · Cited by 63
Gabapentin Abuse in a Cocaine User
Markowitz, J. S., Finkenbine, R., Myrick, H., King, L. Q., & Carson, W. H. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00012 · Cited by 60
Bad medicine: gabapentin and pregabalin
Spence, D. (2013) · BMJ · doi:10.1136/bmj.f6747 · Cited by 60
Pitkälä, K. H., Juola, A.-L., Hosia‐Randell, H., Teramura-Grönblad, M., Soini, H., Savikko, N. M., & Bell, J. S. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.06.009 · Cited by 57
Gabapentin Abuse in Inmates with Prior History of Cocaine Dependence
Reccoppa, L., Malcolm, R. J., & Ware, M. R. (2004) · American Journal on Addictions · doi:10.1080/10550490490460300 · Cited by 57
Felicetti, P., Trotta, F., Bonetto, C., Santuccio, C., Brauchli Pernus, Y., Burgner, D., Chandler, R., Girolomoni, G., Hadden, R. D. M., Kochhar, S., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2015.09.027 · Cited by 50
Pregabalinâs abuse potential: a mini review focusing on the pharmacological profile
Papazisis, G., & Tzachanis, D. (2014) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp202118 · Cited by 49
Carrus, D., & Schifano, F. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318272864d · Cited by 49
Self-citationWHO programme for international drug monitoring
Pal, S. N. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.07.381 · Cited by 49
Sanders, N., Mancino, M. J., Gentry, W. B., Guise, J. B., Bickel, W. K., Thostenson, J., & Oliveto, A. H. (2013) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0033724 · Cited by 44
Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence
Oulis, P., & Konstantakopoulos, G. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.685651 · Cited by 44
Potentiation of the effect of buprenorphine/naloxone with gabapentin or quetiapine
Reeves, R. R., & Ladner, M. E. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13111526 · Cited by 43
LYRICA NIGHTS–RECREATIONAL PREGABALIN ABUSE IN AN URBAN EMERGENCY DEPARTMENT
Millar, J. E., Sadasivan, S. L., Weatherup, N., & Lutton, S. (2013) · Emergency Medicine Journal · doi:10.1136/emermed-2013-203113.20 · Cited by 39
Pregabalin serum levels in apprehended drivers
Kriikku, P., Wilhelm, L., Rintatalo, J., Hurme, J., Kramer, J., & Ojanperä, I. A. (2014) · Forensic Science International · doi:10.1016/j.forsciint.2014.06.030 · Cited by 38
Earlier discovery of pregabalin’s dependence potential might have been possible
Caster, O., Edwards, I. R., Norén, G. N., & Lindquist, M. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0920-4 · Cited by 36
Pregabalin Dependence: A Case Report
Halaby, A., Kassm, S. A., & Naja, W. (2015) · Current Drug Safety · doi:10.2174/1574886309666141022101956 · Cited by 36
Pregabalin og misbrukspotensial
Chalabianloo, F., & Schjott, J. S. (2009) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.08.0047 · Cited by 36
Foster, D. W., Buckner, J. D., Schmidt, N. B., & Zvolensky, M. J. (2016) · Substance Use & Misuse · doi:10.3109/10826084.2015.1082596 · Cited by 34
Pregabalin abuse: a case report / Pregabalin kötüye kullanımı: Bir olgu sunumu
Yargıç, İ., & Özdemiroğlu, F. (2011) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5350/kpb-bcp201121110 · Cited by 33
Brawek, B., Löffler, M., Dooley, D. J., Weyerbrock, A., & Feuerstein, T. J. (2007) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-007-0237-8 · Cited by 33
Drug-related deaths in the UK : Annual Report 2012
Ghodse, A. H., Corkery, J., Claridge, H., Goodair, C., & Schifano, F. (2013) · University of Hertfordshire Research Archive (University of Hertfordshire) · Cited by 32
Self-citationGabapentin Withdrawal: Case Report in an Older Adult and Review of the Literature
Mah, L., & Hart, M. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12427 · Cited by 28
Lourenço, S., Costa, L., Rodrigues, A. M., Carnide, F., & Lucas, R. (2015) · Rheumatology · doi:10.1093/rheumatology/kev110 · Cited by 27
Potential misuse of pregabalin and gabapentin
Loftus, H., & Wright, A. (2014) · BMJ · doi:10.1136/bmj.g1290 · Cited by 27
Pregabalin abuse after past substanceseeking behavior
Papazisis, G., Garyfallos, G., Sardeli, C., & Kouvelas, D. (2013) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp201881 · Cited by 27
Drug safety evaluation of pregabalin
Toth, C. C. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.677026 · Cited by 27
Pregabalin Dependence: A Case Report
Aldemir, E., Altintoprak, E., & Çoşkunol, H. (2014) · Turkish Journal of Psychiatry · doi:10.5080/u7746 · Cited by 26
Socio‐economic risk factors for incident restless legs syndrome in the general population
Szentkirályi, A., Fendrich, K., Hoffmann, W., Happe, S., & Berger, K. (2012) · Journal of Sleep Research · doi:10.1111/j.1365-2869.2012.01001.x · Cited by 21
[Pregabalin--a drug with abuse potential?].
Skopp, G., & Zimmer, G. (2012) · PubMed · Cited by 21
Schmerzmedizin aus einer interkulturellen und geschlechterspezifischen Perspektive
Schiltenwolf, M., & Pogatzki-Zahn, E. M. (2015) · Der Schmerz · doi:10.1007/s00482-015-0038-9 · Cited by 20
Separate dimensions of anxiety differentially predict alcohol use among male juvenile offenders
Nichter, B., & Chassin, L. (2015) · Addictive Behaviors · doi:10.1016/j.addbeh.2015.06.031 · Cited by 19
Gabapentin and pregabalin: abuse and addiction.
(2012) · PubMed · Cited by 19
Trial of Tramadol Plus Gabapentin for Opioid Detoxification
Ziaaddini, H., Ziaaddini, A., Asghari, N., Nakhaee, N., & Shahrbabaki, M. E. (2014) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.18202 · Cited by 17
Safety issues around misuse of antiepileptics
Piskorska, B., Miziak, B., Czuczwar, S. J., & Borowicz, K. K. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.796363 · Cited by 17
Gabapentin for Substance Use Disorders: Is it Safe and Appropriate?
Howland, R. H. (2014) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20131217-01 · Cited by 14
The pain of pregabalin prescribing in prisons
Bicknell, M. (2013) · British Journal of General Practice · doi:10.3399/bjgp13x670615 · Cited by 14
Prevalencia, tipo de epilepsia y uso de fármacos antiepilépticos en atención primaria
Fernández-Suárez, E., Estébanez, R. D. V., Martínez, A. G., Fidalgo-González, J. A., Al-Sibbai, A. A. Z., & Salas‐Puig, J. (2015) · Revista de Neurología · doi:10.33588/rn.6012.2015038 · Cited by 12
Mindfulness Based Interventions for Addictions: What is Next?
Kim Penberthy, J. (2013) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.1000e116 · Cited by 10
A Novel Perspective on Dopaminergic Processing of Human Addiction
Badgaiyan, R. D. (2013) · Journal of Alcoholism and Drug Dependence · doi:10.4172/2329-6488.1000e101 · Cited by 9
Gabapentin: Can It Be Misused?
Howland, R. H. (2014) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20131213-01 · Cited by 8
Nielsen, M., Hansen, E. H., & Gøtzsche, P. C. (2013) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-130594 · Cited by 6
Ghodse, A. H., Corkery, J., Schifano, F., Piolanti, A., Trincas, G., & Melchiorre, G. D. (2012) · Cited by 6
Self-citationMobasher, M., Aldini, S. H. Z., Moghadam, A. H., Sabzevari, F., & Sadeghipour, S. (2004) · Iranian journal of pharmaceutical research · doi:10.22037/ijpr.2010.604 · Cited by 4
Research works printed but not linked: 1
- Sweet AD. Pregabalin abuse and the risks associated for patients with a previous history of substance misuse. J Addict Res Ther 2013;4:e116.
Cited by
Abuse and Misuse of Pregabalin and Gabapentin
Evoy, K. E., Morrison, M. D., & Saklad, S. R. (2017) · Drugs · doi:10.1007/s40265-017-0700-x · Cited by 410
How addictive are gabapentin and pregabalin? A systematic review
Bonnet, U., & Scherbaum, N. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.08.430 · Cited by 281
“Among them, there were 6 detailed postmortem case reports with gabapentin assumed to be the main cause of death (Moore et al., 2005; Middleton, 2011; Cantrell et al., 2015; Chiappini and Schifano, 2016).”
BackgroundMethodInfluentialTompkins, D. A., Hobelmann, J. G., & Compton, P. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.12.002 · Cited by 249
“There is also increasing evidence that patients may misuse or abuse gabapentin (Chiappini and Schifano, 2016; Smith et al., 2016).”
BackgroundAbuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update
Evoy, K. E., Sadrameli, S., Contreras, J., Covvey, J. R., Peckham, A. M., & Morrison, M. D. (2021) · Drugs · doi:10.1007/s40265-020-01432-7 · Cited by 240
Trial of pregabalin for acute and chronic sciatica
Mathieson, S., Maher, C. G., McLachlan, A. J., Latimer, J., Koes, B. W., Hancock, M. J., Harris, I., Day, R. O., Billot, L., Pik, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614292 · Cited by 219
Metadata
- Authors
- Chiappini, S., & Schifano, F.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- University of Hertfordshire (GB)
- Corresponding author
- Chiappini, Stefania
- Venue
- CNS Drugs
- Published
- 2016-06-16
- Volume
- 30
- Issue
- 7
- Pages
- 647-654
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2424370328
- Cited by
- 189
- References
- 68
- Citations by year
- 2026: 8 · 2025: 18 · 2024: 15 · 2023: 19 · 2022: 18 · 2021: 30 · 2020: 20 · 2019: 19 · 2018: 18 · 2017: 22 · 2016: 2
- FWCI
- 20.16
- Type
- journal article
- Language
- en
- Open access
- green
- uhra.herts.ac.uk
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- University of Hertfordshire Research Archive (University of Hertfordshire) (acceptedVersion)
- University of Hertfordshire Research Archive (University of Hertfordshire) (submittedVersion)
- Funders
- European Commission (Drug Prevention and Information Programme 2014-16, contract no. JUST/2013/DPIP/AG/4823, EU-MADNESS project)
- Directorate-General for Justice (JUST/2013/ISEC/DRUGS/AG/6429) Project EPS/NP)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- gabapentinoids, gabapentin, pregabalin, drug abuse, substance dependence, adverse drug reactions, EudraVigilance, drug-related deaths, opioid combination, proportional reporting ratio
- MeSH terms
- Pregabalin, Gabapentin, Adult, Amines, Analgesics, Opioid, Cyclohexanecarboxylic Acids, Female, gamma-Aminobutyric Acid, Humans, Male, Middle Aged, Databases, Factual, Behavior, Addictive, Substance-Related Disorders, Prescription Drug Misuse
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.